Kevin Strange
Kevin Strange, Ph.D. Kevin Strange, Ph.D., became the first president and full-time director of the MDI Biological Laboratory in July 2009 after a career as an NIH-funded biomedical scientist and administrator at Harvard Medical School and Vanderbilt University School of Medicine. As president, Dr. Strange is refocusing the MDI Biological Laboratory’s research program and recruiting multidisciplinary scientists to understand the genetic mechanisms of tissue repair, regeneration, and aging. In 2013, three years after establishing this new research focus, the MDI Biological Laboratory was recognized by the National Institutes of Health as a center of research excellence in regenerative and aging biology and medicine.[1]
Before arriving in Maine, Dr. Strange was associate professor at Harvard Medical School and director of the critical care research laboratories at Children’s Hospital in Boston. In 1997, he moved to Vanderbilt University School of Medicine, where he was the John C. Parker Professor and director of research in the department of anesthesiology.[2]
Dr. Strange is an expert in the field of cellular stress biology. His research focuses on how proteins are damaged by environmental stressors and how cells detect, degrade, and repair these damaged proteins. This work is key to understanding the degenerative changes that occur as humans age. Dr. Strange has published over 125 original papers, review articles, and books. He holds bachelor’s and master’s degrees from the University of California at Davis and received his doctorate from the University of British Columbia.[3]
In 2013, Dr. Strange and assistant professor Voot Yin, Ph.D., founded the MDI Biological Laboratory’s first spinout company, Novo Biosciences, Inc., to accelerate the testing and development of a novel drug for patients with heart disease.[4] That year, the magazine Mainebiz named Dr. Strange one Maine’s ten most “innovative business people” who “hold tremendous promise for the state” and its future economy.[5]